HONG KONG – China biopharmaceutical firm Zai Lab Ltd. bagged marketing approval from Hong Kong's Department of Health this week for its PARP inhibitor, Zejula (niraparib), targeting patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian cancer. It is intended for second-line maintenance use for adult ovarian cancer patients.
HONG KONG – Antibody specialist Hifibio Therapeutics Inc. has picked up French immuno-oncology company H-Immune Therapeutics SAS in a deal that adds pipeline programs, a platform technology and expertise in an increasingly competitive field.
HONG KONG – Antibody specialist Hifibio Therapeutics Inc. has picked up French immuno-oncology company H-Immune Therapeutics SAS in a deal that adds pipeline programs, a platform technology and expertise in an increasingly competitive field.
HONG KONG – China's State Medical Insurance Administration has added 17 cancer drugs to the National Reimbursement Drug List (NRDL) covered by its national basic health insurance, work-related injury insurance and maternity insurance, slashing their prices as much as 74 percent.
HONG KONG – China's State Medical Insurance Administration has added 17 cancer drugs to the National Reimbursement Drug List (NRDL) covered by its national basic health insurance, work-related injury insurance and maternity insurance this week, slashing their prices as much as 74 percent.
HONG KONG – Japan's Daiichi Sankyo Co. Ltd. has moved its HER2-targeting antibody-drug conjugate (ADC), DS-8201 ([fam-] trastuzumab deruxtecan), into a pivotal program, including a study that pits it against Roche Holding AG's Kadcyla (ado-trastuzumab emtansine, TDM-1), an ADC first approved in 2013 that's expected to hit blockbuster status this year.
HONG KONG – Japan's Daiichi Sankyo Co. Ltd. has moved its HER2-targeting antibody-drug conjugate (ADC), DS-8201 ([fam-] trastuzumab deruxtecan), into a pivotal program, including a study that pits it against Roche Holding AG's Kadcyla (ado-trastuzumab emtansine, TDM-1), an ADC first approved in 2013 that's expected to hit blockbuster status this year.
